Evidence map›Paper›PMID 26082974›Full record

Trial reportJournal of clinical psychopharmacology2015

Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.

Deanna L Kelly, Kelli M Sullivan, Joseph P McEvoy, Robert P McMahon, Heidi J Wehring, James M Gold, Fang Liu, Dale Warfel, Gopal Vyas, Charles M Richardson and 11 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical psychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 7 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 7 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Analysis of clinical studies on clozapine from 2012-2022.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  13. Article
  14. Augmentation Strategies for Partial or Non-responders to Clozapine in Patients with Schizophrenia: A Bayesian Network Meta-analysis of Randomized Controlled Trials.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Deanna L KellyFrom the *Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD; †Department of Psychiatry, Georgia Regents University, Medical College of Georgia, Augusta, GA; ‡Department of Psychiatry, Clinical Research Program, Sheppard Pratt Health System and University of Maryland School of Medicine, Baltimore, MD; and §Department of Psychiatry, Psychology and Neuroscience, Duke University School of Medicine, Durham, NC.
Kelli M Sullivan
Joseph P McEvoy
Robert P McMahon
Heidi J Wehring
James M Gold
Fang Liu
Dale Warfel
Gopal Vyas
Charles M Richardson
Bernard A Fischer
William R Keller
Maju Mathew Koola
Stephanie M Feldman
Jessica C Russ
Richard S E Keefe
Jennifer Osing
Leeka Hubzin
Sharon August
Trina M Walker
Robert W Buchanan
University of Maryland, Baltimore · USAugusta University · USSheppard Pratt Health System · US

Funding

Adjunctive Minocycline in Clozapine Treated Patients for Psychosis and CognitionR21MH091184 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI KELLY, DEANNA L · 2011 to 2012
$413k
NIMH NIH HHS R21 MH091184NIMH NIH HHS R21MH091184-01A1
6 · The paper itself

Abstract

objectiveClozapine is the most effective antipsychotic for treatment refractory people with schizophrenia, yet many patients only partially respond. Accumulating preclinical and clinical data suggest benefits with minocycline. We tested adjunct minocycline to clozapine in a 10-week, double-blind, placebo-controlled trial. Primary outcomes tested were positive, and cognitive symptoms, while avolition, anxiety/depression, and negative symptoms were secondary outcomes.

methodsSchizophrenia and schizoaffective participants (n = 52) with persistent positive symptoms were randomized to receive adjunct minocycline (100 mg oral capsule twice daily; n = 29) or placebo (n = 23).

resultsBrief Psychiatric Rating Scale (BPRS) psychosis factor (P = 0.098; effect size [ES], 0.39) and BPRS total score (P = 0.075; ES, 0.55) were not significant. A change in total BPRS symptoms of more than or equal to 30% was observed in 7 (25%) of 28 among minocycline and 1 (4%) of 23 among placebo participants, respectively (P = 0.044). Global cognitive function (MATRICS Consensus Cognitive Battery) did not differ, although there was a significant variation in size of treatment effects among cognitive domains (P = 0.03), with significant improvement in working memory favoring minocycline (P = 0.023; ES, 0.41). The Scale for the Assessment of Negative Symptoms total score did not differ, but significant improvement in avolition with minocycline was noted (P = 0.012; ES, 0.34). Significant improvement in the BPRS anxiety/depression factor was observed with minocycline (P = 0.028; ES, 0.49). Minocycline was well tolerated with significantly fewer headaches and constipation compared with placebo.

conclusionsMinocycline's effect on the MATRICS Consensus Cognitive Battery composite score and positive symptoms were not statistically significant. Significant improvements with minocycline were seen in working memory, avolition, and anxiety/depressive symptoms in a chronic population with persistent symptoms. Larger studies are needed to validate these findings.

Indexed as

Schizophrenic PsychologyAdultAntipsychotic AgentsClozapineDouble-Blind MethodDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMinocyclineSchizophreniaTreatment OutcomeAntipsychotic AgentsClozapineMinocycline

Identifiers

PMID26082974
PMCPMC4485552
OpenAlexW2406359697

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.